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Available online 01 December 2016Multipotent stromal cells (MSCs) are envisioned as a powerful therapeutic tool. As they home into tumors, se-
crete trophic and vasculogenic factors, and suppress immune response their role in carcinogenesis is a matter
of controversy. Worldwide oral squamous cell carcinoma (OSCC) is the ﬁfth most common epithelial cancer.
Our aimwas to determinewhetherMSC administration at precancerous stagemodiﬁes the natural progression of
OSCC.
OSCCwas induced in Syrian hamsters by topical application of DMBA in the buccal pouch. At papilloma stage, the
vehicle or 3 × 106 allogenic bone marrow-derived MSCs were locally administered. Four weeks later, the lesions
were studied according to: volume, stratiﬁcation (histology), proliferation (Ki-67), apoptosis (Caspase 3
cleaved), vasculature (ASMA), inﬂammation (Leukocyte inﬁltrate), differentiation (CK1 and CK4) and gene ex-
pression proﬁle (mRNA).
Tumors found in individuals that receivedMSCswere smaller than those presented in the vehicle group (87±80
versus 54 ± 62 mm3, p b 0.05). The rate of proliferation was two times lower and the apoptosis was 2.5 times
higher in lesions treated with MSCs than in untreated ones. While the laters presented dedifferentiated cells,
the former maintained differentiated cells (cytokeratin and gene expression proﬁle similar to normal tissue).
Thus, MSC administration at papilloma stage precludes tumor growth and epithelial dedifferentiation of OSCC.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Papilloma1. Introduction
Multipotent stromal cells, also referred to as mesenchymal stem cells
(MSCs), are an heterogeneous subset of stromal cells present in several
tissues including bone marrow, bone, adipose tissue, skin, kidney, umbil-
ical cord and placenta (Friedenstein et al., 1968). The minimal criteria for
deﬁning MSCs are adherence to plastic surface; proliferation under the
stimulus of fetal bovine serum; no expression of hematopoietic markers;
expression of CD73, CD90, CD105, and differentiation into mesodermal
cells (adipocytes, chondrocytes and osteocytes) (Dominici et al., 2006).
MSCs are envisioned as an ideal tool for cell therapy since they home
into injured tissues whereas they could differentiate into tissue-speciﬁc
cells (Ezquer et al., 2011), manage oxidative stress (Valle-Prieto and
Conget, 2010), release trophic factors (Caplan and Dennis, 2006), pro-
mote neovascularization (Ball et al., 2007) or trigger an anti-inﬂamma-
tory response (Uccelli and Prockop, 2010). It has been shown that donor
MSCs also home into stablished tumors where they interact with cancernerativa, Facultad de Medicina
es, 12,438, Santiago, Chile.
nget@udd.cl (P. Conget).
en access article under the CC BY-NCstem cells, regulate neovascularization and modulate the immune re-
sponse (Al Moustafa et al., 2002; Bolontrade et al., 2012).
Currently, the role of MSCs in carcinogenesis is a matter of contro-
versy. It has been reported that they favor tumor growth due to the im-
munosuppression (Djouad et al., 2003). Also, MSCs could enhance
tumor metastatic potential since they can induce epithelia to mesen-
chyme transition (Huang et al., 2013). In contrast, it has been shown
that MSCs inhibit tumorigenesis (Balasenthil et al., 2002a). The mecha-
nisms apparently related to the antitumor effect could be: i) induction
of cancer cell apoptosis (Ho et al., 2013), ii) avoidance of epithelium de-
differentiation (Ho et al., 2013), iii) inhibition of vascular network for-
mation or apoptosis of vascular endothelial cells (Otsu et al., 2009;
Secchiero et al., 2010), and iv) stimulation of anti-tumor immune re-
sponse (Madrigal et al., 2014).
Worldwide oral squamous cell carcinoma (OSCC) is the ﬁfth most
common epithelial cancer, its annual incidence is over 300,000 diag-
nosed cases and its annual mortality is about 145,000 deaths (Rivera,
2015). Despite advances in its detection and treatment the mortality
of OSCC remains high and its ﬁve-year survival rate is among the lowest
of the major cancers (Rivera, 2015).
OSCC goes from normal keratinocyte transformation to randommu-
tations linked to epigenetic processes that deregulate DNA repair-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Thus, normal tissue evolves progressively through hyperplasia, dyspla-
sia and carcinoma in situ until reaching the stage of invasive carcinoma
(Rivera, 2015; Dvorak et al., 2011; Nishimura et al., 2012; Choi and
Chen, 2005; Mendez et al., 2002; Arora et al., 2005).
The disease developed in the Syrian golden hamster using themuta-
gen 7.12-dimethylbenz-alpha-anthracene (DMBA) is a widely accepted
animal model of OSCC (Chen et al., 2002; Nagini et al., 2009). It shares
morphological, histological and molecular markers with human OSCC
progression (Hasina et al., 2009; Ezquer et al., 2015; Aromando et al.,
2014; Brandwein-Gensler et al., 2005).
The aim of this work was to determinewhether MSC administration
at precancerous stagemodiﬁes the natural progression of OSCC. For this,
OSCC was induced in hamsters by topical application of DMBA in the
buccal pouch. At papilloma stage, the vehicle or 3 × 106 allogenic bone
marrow-derived MSCs were locally administered. Four weeks later,
the lesions were studied according to their: volume (macroscopy), his-
tology (H&E staining), rate of proliferation (immunohistoﬂuorescence
for Ki-67), rate of apoptosis (TUNEL), density of vasculature
(immunohistoﬂuorescence for ASMA), degree of inﬂammation (H&E
and Toluidine blue staining), degree of differentiation (CK1 and CK4
immunohistoﬂuorescence) and gene expression proﬁle (RT-qPCR)
(Supplementary Fig. 1).2. Materials and methods
2.1. Animals
A total of 151 Syrian golden hamsters (Mesocricetus auratus) were
used in this study. Nineteen were unmanipulated (5 used in OSCC nat-
ural progression study and 14 used in gene expression study), 56 served
asMSC donors and 76 were OSCC induced (5 hyperplasia, 5 dysplasia, 5
papilloma and 5 carcinoma used in OSCC natural progression study; 14
OSCC+ vehicle and 14 OSCC+MSC used for macroscopical andmicro-
scopical analysis, 14 OSCC+ vehicle and 14 OSCC+MSC used for gene
expression analysis).
Protocol was approved by the Ethic Committee of Facultad de
Medicina Clinica Alemana-Universidad del Desarrollo (approval ID:
2011–14).2.2. OSCC induction
Healthymale hamsters, eight weeks old, were painted thrice a week
into their right buccal pouche with a N°4 camel-hair brush soaked with
50uL ofmineral oil (Sigma-Aldrich, St. Louis,MO) or 50uL of 0.5% DMBA
(Sigma-Aldrich) dissolved in mineral oil (Schwartz et al., 1988).
Animals were housed at 22 °C, with a 12:12 h light-dark cycle, and
water and food ad libitum.2.3. Macroscopical analysis of OSCC progression
Nine and 13 weeks after the initiation of OSCC induction, hamsters
were anesthetized by intraperitoneal injection of 20 mg/kg Xylazine
(Centrovet, Santiago, Chile) and 20 mg/kg Ketamine (Ilium, Buenos
Aires, Argentina). Buccal pouches were uncovered, and tumors were
measured with a digital caliper (Mitutoyo Sul Americana LTDA, Brazil)
and photographed using a digital camera (FUJIFILM-Finepi HS20 EXR).
Two independent observers analyzed the photographs and described
the lesions according to the presence of eritroplakia, leukoplakia,
vascularization and exophytic or ulcerated rolled border nodules.
The lesion volume was calculated using the formula: tumor volume
(mm3)= 0.52 × [width (mm)]2 × length (mm) and the tumor increase
was estimated as the ratio between ﬁnal and initial volumes (Suzuki
et al., 2011).2.4. Microscopical analysis of OSCC progression
Four weeks after vehicle or MSC administration, hamsters were eu-
thanized by an intraperitoneal injection of an overdose of Xylazine
and Ketamine. Buccal pouches were procured and tumors were
resected. Tumor specimens were ﬁxed in 10% buffered formalin
(Merck, USA), embedded in parafﬁn (Merck) and sectioned. Tissue sec-
tions of 4 μm were deparafﬁnized with Neoclear (Merck), rehydrated
with graded alcohols, stained with H&E (Merck) and visualized with a
light microscope (DM2000, Leica, Germany). Images were captured
with a digital camera (DFC295, Leica). Tumor stage (hyperplasia, dys-
plasia, papilloma or carcinoma) was stated as previously described
(Schwartz et al., 1988).
Histological analysis was performed in blind by three independent
observers; one of them is a pathologist expert in oral diseases.2.5. MSC isolation, ex vivo expansion and characterization
Healthy female hamsters, eight weeks old, were euthanized by an
intraperitoneal injection of an overdose of Xylazine and Ketamine. Fe-
murs and tibias were procured under sterile conditions. The epiﬁsis
were removed and bone marrow was collect by ﬂushing bones with
sterile phosphate buffer saline (PBS) (Gibco, Auckland, NZ). Recovered
cells were resuspended in alpha-MEM (Gibco) supplemented with
10% fetal bovine serum (FBS, Gibco) and 40 mg/mL gentamycin
(Sanderson Laboratory, Chile), and plated at a density of 0.25 × 106 nu-
cleated cells/cm2. Every three days, culture medium was changed.
When foci reached conﬂuence, adherent cells were detached with
0.25% trypsin, 2.65 mM EDTA (Gibco). After one subculture, cells were
characterized and transplanted.
Immunophenotyping was performed by ﬂow cytometry after im-
munostainingwith APC-conjugated mouse anti-CD45 (BD Pharmingen,
San Diego, USA), FITC-conjugated mouse anti-ASMA (Sigma), FITC-con-
jugated mouse anti-vimentin (Oncogen, USA) (Bartholomew et al.,
2002). To assess the differentiation potential, cells were incubated
with adipogenic or osteogenic differentiation media (Contador et al.,
2015; Conget and Minguell, 1999). Seven and 14 days later, they were
stained with Oil Red O or Alizarin Red, respectively.2.6. MSC administration
When lesions reached the stage of papilloma, animalswere random-
ly distributed to experimental groups, anesthetized and their buccal
pouchs were exposed using a surgical forceps. Using a 23-gauge needle
(Terumo, Tokio, Japón), 400 μL of 5% hamster plasma (vehicle) or
3 × 106 MSCs resuspended in 5% hamster plasma were injected into
the mucosa around the lesions (Cavalieri and Rogan, 1992).2.7. Proliferation assessment
Tissue sections of 5 μm were deparafﬁnized and rehydrated. After
blocking with 5% FBS, samples were incubated overnight at 4 °C with
a dilution 1:50 of rabbit anti-K-i67 polyclonal serum (Abcam, USA).
Then, samples were washed and incubated 2 h at room temperature
with a dilution 1:400 of Alexa488-conjugated goat anti-rabbit IgG
(Cell Signaling, Massachusetts, USA). Cross-reactivity of the secondary
antibody was tested incubating tissue sections without the primary an-
tibody. Nuclei were counterstained with a dilution 1:1500 of DAPI
(Invitrogen, California, USA). Samples were observed in a ﬂuorescence
microscope. Images were captured with a digital camera and analyzed
using Image J software (NIH Image J). The rate of proliferation was cal-
culated as the quotient between Ki-67-positive cells and the total num-
ber of cells, counted in ﬁve representative optical sections (at least 1000
nuclei) using 40× magniﬁcation (Hasina et al., 2009).
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Tissue sections of 4 μm were deparafﬁnized, rehydrated, digested
with 20 μg/mL proteinase K (Invitrogen) and labeled, followingman-
ufacturer instructions, with a terminal deoxynucleotidyl transferase
dUTP nick 3′end-labeling (TUNEL) kit (Promega, USA). Nuclei were
counterstained with a dilution 1:1500 of DAPI. Samples were
observed in a ﬂuorescence microscope. Images were captured with
a digital camera and analyzed using Image J software. The rate of ap-
optosis was expressed as the number of TUNEL-positive cells per
1000 cells, observed in ten representative optical sections using
40× magniﬁcation. Areas with extensive necrosis were avoided
(Ezquer et al., 2015).2.9. Vascularization assessment
Tissue sections of 4 μm were deparafﬁnized, rehydrated, blocked
with 5% FBS and incubated overnight at 4 °C with a dilution 1:50 of
mouse anti-ASMA (Cell Marque, Rocklin, USA). Then, samples were
washed and incubated two h at room temperature with a dilution
1:400 of Alexa488-conjugated goat anti-mouse IgG (Cell Signaling,
USA). Cross-reactivity of the secondary antibody was tested incubating
samples without the primary antibody. Nuclei were counterstained with
a dilution 1:1500 of DAPI. Samples were observed in a ﬂuorescence mi-
croscope, images were captured with a digital camera and analyzed
using Image J software. The density of vasculature was expressed as the
number of ASMA-positive vessels per ﬁeld, observed in ﬁve representa-
tive optical sections using 40× magniﬁcation (Aromando et al., 2014).Fig. 1. OSCC progression. (First line) Macroscopy of buccal pouch. At dysplasia stage blood ves
arrow). (Second line) Histology (H&E) of buccal pouch. The epithelium thickness
Immunohistoﬂuorescence for ASMA. The vascularization changes over OSCC progression (whi
(asterisk). Epithelial atypical cells were observed over OSCC progression (black arrow). Bar =
Bar = 50 μm. Representative images (n= 5).2.10. Inﬂammation assessment
Tissue sections of 4 μm were deparafﬁnized, rehydrated and
stained with H&E or with 1% Toluidine blue (Merck) in 1% sodium
chloride solution (Sigma). Samples were visualized with a light mi-
croscope. Images were captured with a digital camera. The degree
of inﬂammation was classiﬁed according to the score: absent (−),
low (+), moderate (++) and severe (+++) (Brandwein-Gensler
et al., 2005). The number of inﬁltrated mast cells was expressed
as the number of metachromatic cells per ﬁeld, observed in ﬁve
representative optical sections using 40× magniﬁcation (Zaidi and
Mallick, 2014).2.11. Differentiation assessment
Tissue sections of 4 μm were deparafﬁnized, rehydrated, blocked
with 5% FBS and incubated overnight at 4 °C with a dilution 1:50 of
mouse anti-cytokeratin 1 (CK1, Abcam, Cambridge, UK) or mouse
anti-cytokeratin 4 (CK4, Abcam). Then, samples were washed and
incubated 2 h at room temperature with a dilution 1:400 of Alexa
488-conjugated goat anti-mouse IgG. Cross-reactivity of the second-
ary antibody was tested incubating samples without the primary
antibody. Nuclei were counterstained with a dilution 1:1500 of
DAPI. Samples were observed in a ﬂuorescence microscope, images
were captured with a digital camera and analyzed using Image J soft-
ware. The expression of CK1 and CK4 was recorded as pixels intensi-
ty, in ﬁve representative optical sections using 40× magniﬁcation
(Caster and Kahn, 2012).sels were noticeable (arrow head). At papilloma stage, exophytic lesions appeared (black
changes over OSCC progression (square bracket). Bar = 100 μm. (Third line)
te arrow). Bar = 100 μm. (Fourth line) Histology (H&E) focusing in leukocyte inﬁltration
50 μm. (Fifth and Sixth lines) Immunohistoﬂuorescence for CK1 and CK4, respectively.
Fig. 2. Characterization ofMSCs isolated from Syrian golden hamster bonemarrow. (A) Immunophenotype of cells.White area= isotype control. (B) Differentiation assay. Bar= 100 μm.
Representative data (n= 4).
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Total RNAwas isolated from buccal pouches using RNEasy PlusMini
Kit (Qiagen, Hilden, Germany). Contaminating genomic DNA wasFig. 3.MSC administration precludes OSCC tumor growth. (A) Tumor volume before (pre-) or
(OSCC +MSCs). (B) Tumors increase four weeks after the administration of the vehicle (OSCC
after the administration of the vehicle (OSCC + vehicle) or 3 × 106 cells (OSCC + MSCs). Blac
arrow = epithelium invasion. Bar = 100 μm. Representative data (n= 14).degraded with DNAse RQ1 (Promega). One μg of RNAwas reverse tran-
scribed for 60 min at 42 °C using 200 U M-MLV reverse transcriptase
(Invitrogen) and 0.5 μM oligo-dT primers (Invitrogen). Real time PCR
was performed in a ﬁnal volume of 10 μL containing 50 ng of cDNA,four weeks after (post-) the administration of vehicle (OSCC + vehicle) or 3 × 106 cells
+ vehicle) or 3 × 106 cells (OSCC + MSCs). (C) Macroscopy of buccal pouch four weeks
k arrow = necrosis features. Bar = 300 mm. (D) Histology (H&E) of buccal pouch. Black
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NY) and 0.5 μMof each speciﬁc primer, using the Step One Plus PCR sys-
tem(Life Technologies). Controlswithout reverse transcriptasewere in-
cluded. Amplicons were analyzed according to their size and melting
temperature (Supplementary Table 1). To normalize data, 18S RNA
was used as reference gene (Tobar et al., 2010). ThemRNA level of a tar-
get gene was calculated using the 2ΔCt method and graphed as arbi-
trary units (a.u.) (Schmittgen and Livak, 2008).
2.13. Statistical analysis
As population distribution was non-parametric, comparison among
groups were performed using one-way ANOVA test and Dunn's test as
post-test. To compare between two groups, Tukey's test was used.
StatGraph Prism 5.0 software was used for statistical analysis. Data are
presented as median ± SEM. p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Natural progression of OSCC tumors
Buccal pouchs in normal hamsterswere elastic and translucid (Fig. 1,
ﬁrst column). The epithelium was continuous and presented no more
than four cell layers with scarce vasculature and absence of inﬂamma-
tion. CK1 was present in the epithelial basal cell layer and CK4 in the
suprabasal cell layer.
The exposure to DMBA for four weeks resulted in hyperplasia
(Fig. 1, second column). Buccal pouch retracted and showed leuko-
plakia and/or erythroplakia, accompanied by an engrossment of the
mucosa due to inﬂammation. The epithelium showed 6–8 cell layers,
no evidence of cell atypias or nuclear hypercromatism was found.
Vessel size was increased and a few leukocyte foci were found. CK1Fig. 4. MSC administration decreases proliferation and increases apoptosis in OSCC tumors
(OSCC +MSCs), (A) immunohistoﬂuorescence for Ki-67 and (B) TUNEL assay. Bar = 50 μm. Rwas present in the basal and suprabasal cell layers, and CK4 was in-
creased in the suprabasal layer.
Dysplasia stage is evident after six weeks of exposure to DMBA
(Fig. 1, third column). Buccal pouch engrossed and lose elasticity. The
epithelium showed more than eight cell layers without invasion in to
the stroma. An increase in vessel size and number, together with mod-
erate leukocyte foci were observed. In addition, atypical cells were
found. CK1 localized in the basal and CK4 in the suprabasal cell layers,
both were over expressed.
At week 9 after ﬁrst DMBA application papillomas appeared
(Fig. 1, fourth column). Those exophytic lesions did not extend into
the connective tissue but outgrowth from the surface. The histologi-
cal analysis showed features of atypical cells in the epithelial layer
but not invading the submucosal connective tissue. The number
and size of vessels were increased in the stroma and epithelium
compared with normal buccal pouch. Inﬂammation around the le-
sions was moderated. CK1 was undetectable and CK4 was increased
and lose is suprabasal localization.
Carcinoma stage is reached after 13 weeks of exposure to DMBA
(Fig. 1, ﬁfth column). Buccal pouchs were contracted and stiffs, with
features of necrosis. Epithelium showed abundant cell and nuclear
pleomorphism, the stratiﬁcation was lost and basal membrane was dis-
continuous. Aberrant vessels (large size and discontinuouswall) and in-
ﬂammatory focus were abundant. CK1 disappeared and CK4 increased,
being noticeable in all epithelial cell layers.
3.2. Phenotype of hamster MSCs
Adherent cells isolated fromhamster bonemarrow showed spindle-
ﬁbroblastic morphology and proliferate under the stimuli of FBS. They
were negative for the hematopoietic marker CD45 and positive for the
mesenchymal markers ASMA and vimentin (Fig. 2A). After exposure
to the adipocyte differentiation medium, lipid drops stained with Oil
RedOwere observed (Fig. 2B). Exposure to the osteocyte differentiation. Four weeks after the administration of the vehicle (OSCC + vehicle) or 3 × 106 cells
epresentative images (n= 8).
Fig. 5.MSC administration does not modify OSCC tumor vasculature density. Four weeks after the administration of the vehicle (OSCC + vehicle) or 3 × 106 cells (OSCC + MSCs), (A)
immunohistoﬂuorescence for ASMA. (B) Quantitative analysis. White arrow = vessel. Bar = 50 μm. Representative images (n= 5).
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Alizarin Red.
3.3. MSC administration precludes tumor growth and modiﬁes the natural
progression of OSCC tumors
Before MSC administration, 100% of the animals developed papillo-
ma lesions which volume ranged from 1 to 50 mm3. Four weeks later,
all the hamsters presented tumors. Lesions receiving the vehicle
grown up to 10 to 325 mm3 and those receiving MSCs reached 5 to
220 mm3 (Fig. 3A). Tumor volumes expressed as median ± SEM were
87± 80 and 54± 62 mm3, respectively (p b 0.05). Together, tumor in-
crease was three times lower in the later compared with the former
(p b 0.05) (Fig. 3B). Population analysis showed that in the
OSCC + vehicle group 90% of the animals presented tumors bigger
than 100 mm3, while in OSCC + MSCs group only 20% do so.Fig. 6.MSC administration does not modify OSCC tumor inﬂammation. Four weeks after the adm
(H&E) focusing in leukocyte inﬁltration. EC = epithelial cells, ST = stroma, TC = tumor cells. G
absent (−), low (+),moderate (++) and severe (+++). (B) Toluidine blue staining. Graphs
(n= 5).Tumors developed in animals that received the vehicle presented
histological characteristics pathognomonic of carcinoma stage including
necrosis features, poorly differentiated epithelial cells, disorganized
basal cell layer and cell invasion into the stroma (Fig. 3C). In constrast,
in the animals transplanted with MSCs the tumors presented no necro-
sis, well-differentiated epithelial cells and continuous basal layer.
3.4. MSC administration decreases the rate of proliferation and increases
the rate of apoptosis in OSCC tumors
The rate of proliferation was signiﬁcantly lower in the tumors of
hamsters that receivedMSCs comparedwith those that received the ve-
hicle (18 ± 7 versus 8 ± 4 Ki-67-positive cells/100 cells, p b 0.05)
(Fig. 4A). Conversely, the rate of apoptosis was signiﬁcantly higher in
the former compared with the later (9 ± 4 versus 21 ± 16 TUNEL-pos-
itive cells/100 cells, p b 0.05) (Fig. 4B).inistration of the vehicle (OSCC+ vehicle) or 3 × 106 cells (OSCC+MSCs), (A) histology
raphs show quantitative analysis of leukocyte inﬁltrate according to the following score:
show quantitative analysis of mast cells abundance. Bar = 50 μm. Representative images
11F. Bruna et al. / Stem Cell Research 18 (2017) 5–133.5. MSC administrationmodiﬁed neither the density of vasculature nor the
degree of inﬂammation in OSCC tumors
Irrespective of MSC administration, tumors presented large blood
vessels with wall discontinuity (Fig. 5A). Their abundance was higher
than observed in normal tissue (Fig. 5B).
MSC administration did not modify tumor inﬂammation evaluated
as either leucocyte or mast cell inﬁltration (Fig. 6).
3.6. MSC administration prevents epithelial dedifferentiation in OSCC
tumors
In papilloma lesions treated with MSCs it was possible to detect CK1
(Fig. 7A). On another hand, CK4 expressionwas restricted to the epithe-
lium cell layer and epithelial cells invading the stroma (nest sheets) and
its total level was lower in lesions receivingMSCs compared to those re-
ceiving the vehicle (Fig. 7A).
Quantitative analysis of mRNA levels of ECGR2 (proliferation re-
lated gene), BTC (survival related gene), TRIM2 (migration related
gene) and EAF2 (transcriptional activity related gene) showed that,Fig. 7.MSC administration precludes OSCC tumor epithelial dedifferentiation. Four weeks afte
immunohistoﬂuorescence for CK1 and CK4. Graphs show quantitative analysis. White bar = 5
(n= 14).compared with untreated OSCC, these genes were signiﬁcantly
down-regulated in the lesions treated with MSCs, reaching normal
values (Fig. 7B).
4. Discussion
The effect of donor MSCs in tumor growth remains controversial
(Cho et al., 2009). Discrepancies concerned to whether they promote
or suppress it may be due to disparities in cell source, isolation and ex-
pansion conditions, via and timing of administration, cancer model,
timing of assessment, etc. (Ikebe and Suzuki, 2014). Up to our knowl-
edge, the impact of donorMSCs in precancerous lesions has not been re-
ported.We decided to test it in the OSCCmodel settled in Syrian golden
hamster because it mimics the etiology (DMBA is present in cigarrette
smoke), the progression and the response to chemopreventive agents
of human OSCC (Nagini et al., 2009). Together, changes are grossly vis-
ible and patognomonic of each stage (Nagini et al., 2009).When we ad-
ministered 0.1 × 106 or 1 × 106MSCs to OSCC lesions at papilloma stage
we observed a reduction in tumor size (Supplementary Fig. 2). This ef-
fect was more signiﬁcant when we administered 3 × 106 MSCs (Fig. 3).r the administration of the vehicle (OSCC + vehicle) or 3 × 106 cells (OSCC +MSCs), (A)
0 μm. (n= 5). (C) Gene expression of ECG2, BTC, Trim2 and Eaf2. Representative images
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crease in cell proliferation and an increase in cell apoptosis. Both con-
strain tumor size enlargement. These results are consistent with
previous works reporting that MSC administration inhibits established
tumor growth through proliferation inhibition and apoptosis induction
(Ramasamy et al., 2007; Qiao et al., 2008; Glennie et al., 2005; Beyth
et al., 2005).
Neovascularization plays a central role in the development and
progression of tumors including OSCC (Li et al., 2007). It has been
previously shown that MSCs differentiate and secrete vasculogenic
growth factors supporting tumor vasculature (Roorda et al., 2009).
In a glioma animalmodel it has been shown that the systemic admin-
istration of MSCs reduced the number and caliber of tumor vessels
(Ho et al., 2013). Thus, depending on yet undeﬁned variables MSCs
can promote or inhibit neovascularization. Under the setting here
presented, donor MSCs does not modify the vasculature of OSCC
lesions (Fig. 5).
Since neoplastic microenvironment is similar to that of an injured
tissue. Man (2010) donor MSCs delivered around OSCC papilloma
could trigger a non-speciﬁc allogeneic immune response that might im-
pedes tumor growth. At the end of the study periodwe observed no dif-
ferences in the inﬁltration of leukocyte or mast cells (ﬁrst host line
defense in the oral mucosa (Coussens et al., 1999)). Thus, chronic
immunomodulation does not explain MSC anti-tumorigenic effect. We
cannot rule out that acute immunomodulation is involved.
Cytokeratins are epithelial speciﬁc intermediate ﬁlament proteins,
underlying distinct cellular properties and differentiation stages
(Schweizer et al., 2006). In the hamster buccal pouch, the epithelial
basal cell layer expresses CK1 while the suprabasal cell layer express
CK4 (Balasenthil et al., 2002a; Balasenthil et al., 2002b). Alterations in
CK1 andCK4 expression are sensitivemarkers for epithelial tumor strat-
iﬁcation (Ogden et al., 1996). Thus, the observed recovery of CK1 ex-
pression and the normalization of CK4 tissue distribution after MSC
administration reﬂect an avoidance of epithelium dedifferentiation. Ac-
cordingly, it has been reported that MSCs stabilize cell phenotype of
keratinocytes, endothelial cells, pericytes and monocytes in wound re-
pair (Sasaki et al., 2008). Further support to the preclusion of dedifferen-
tiation is the normalization of gene expression proﬁle after MSC
administration (Fig. 7B). The later has been observed in other oral path-
ological conditions (Dowdall et al., 2015). Thepreservation of a differen-
tiated phenotypemay be attributed to the potential of MSCs to sustain a
homeostatic microenvironment, particularly scavenging oxidative
stress (Valle-Prieto and Conget, 2010; Ramasamy et al., 2007).
Taken together, our results support an anti-tumorigenic effect of
MSCs in epithelial precancerous lesions. Thus, the local administration
of allogeneic MSCs should be envisioned as a preventive strategy for
the development of OSCC since donor cells modify its natural progres-
sion and improve prognosis due to the preservation of epithelial pheno-
type. This is not an irrelevant goal in the ﬁeld since the prognosis for
patients with OSCC still poor (Jadhav and Gupta, 2013).
5. Conclusion
The local administration of allogenic bonemarrow-derived MSCs, at
papilloma stage, precludes tumor growth and epithelial dedifferentia-
tion of OSCC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.11.016.
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